Sobi to buy Dova Pharmaceuticals in £915m deal
This article was originally published here
The deal to acquire Dova Pharmaceuticals includes an upfront payment of $27.50 (£22.35) per share in cash, as well as one non-tradeable contingent value right (CVR). Dova Pharmaceuticals
The post Sobi to buy Dova Pharmaceuticals in £915m deal appeared first on Pharmaceutical Business review.
Leave a Reply
Want to join the discussion?Feel free to contribute!